CME Group names David Boberski MD, OTC research and new product development

Source: CME Group

CME Group, the world's largest and most diverse derivatives exchange, today announced that it has named David Boberski as Managing Director, OTC Research and New Product Development.

In this newly created position, Boberski, 33, will be responsible for identifying and developing new product opportunities in credit and interest rates, adapting existing CME Group products and services to the over-the-counter (OTC) markets and educating CME Group customers on CME Group credit and interest rate products. He will report to Julie Winkler, Managing Director, Research and Product Development.

Prior to joining CME Group, Boberski most recently worked as a consulting expert for the U.S. Commodity Futures Trading Commission's Division of Enforcement. He also has served as Executive Director and Head of Exchange Traded Derivatives Research for UBS Investment Bank and Managing Director, Principal and Head of Interest Rate Strategy for Bear, Stearns and Co., where he gained extensive experience in OTC derivatives. He also worked as an Adjunct Professor in Portfolio Theory Economics at the University of Illinois.

Boberski earned bachelor's degrees in economics and finance from the College of William and Mary, a master's degree in economics from the University of Chicago and a master's degree in finance from the University of Illinois. He has published two books and has been named to the Institutional Investor All-American Research Team. He is a Series 3, 7, 16 and 63 Registered Representative.

Comments: (0)

Find out more
Dorsum white paper - Building your future wealth management solution vol. 2